Inovio Pharmaceuticals

Inovio Pharmaceuticals

INO· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -4.9% in FY2025

Jacqueline E. Shea, Ph.D. is the CEO of Inovio Pharmaceuticals and was paid $1.6M in FY2025 (Dec), down 23%.

Pay$100 in the stock at the end of FY21 → $3
CEO pay is from each Inovio Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Jacqueline E. Shea, Ph.D.FY2025
  2. 2Michael SumnerFY2025
  3. 3Peter D. KiesFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Inovio Pharmaceuticals paid its 3 named executives $3.3M in total in FY2025 (Dec). CEO Jacqueline E. Shea, Ph.D. was paid $1.6M of that.

Name
Jacqueline E. Shea, Ph.D.President and Chief Executive Officer
Michael SumnerM.D. Chief Medical Officer and Head of DevelopmentNot disclosed
Peter D. KiesChief Financial Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers20

See all

The FY2024 (Dec) proxy of Inovio Pharmaceuticals names 20 peer companies for pay. Among Inovio Pharmaceuticals and these peers, CEO pay was the lowest of 6 and total shareholder return was the lowest of 6.

6th highest of 6in Inovio Pharmaceuticals and its pay peers, FY2024 (Dec) by CEO pay:

$2.1M$18.8M

6th highest of 6in Inovio Pharmaceuticals and its pay peers, FY2024 (Dec) by total shareholder return:

$3$271

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board3

See all
  • Wendy L. YarnoDirector · 8 yr on the boardIndependentCompensation (Chair), Nomination and Corporate Governance—Paid as an executive
  • Jay P. ShepardDirector · 5 yr on the boardIndependentAudit, Nomination and Corporate Governance—Paid as an executive
  • Roger D. Dansey, M.D.Director · 4 yr on the boardIndependentNomination and Corporate Governance—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Inovio Pharmaceuticals CFO pay fell 11% to $833.7K. The stock fell 5% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Inovio Pharmaceuticals Division head pay fell 12% to $910.6K. The stock fell 5% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Inovio Pharmaceuticals CEO pay fell 23% to $1.6M. The stock fell 5% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Inovio Pharmaceuticals CFO pay fell 19% to $940.1K. The stock fell 70% in FY2024 (Dec).
    DEF 14A
  5. Pay
    Inovio Pharmaceuticals CEO pay fell 16% to $2.1M. The stock fell 70% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Inovio Pharmaceuticals CFO pay fell 28% to $1.2M. The stock fell 67% in FY2023 (Dec).
    DEF 14A
  7. Pay
    Inovio Pharmaceuticals Division head pay fell 27% to $1.1M. The stock fell 67% in FY2023 (Dec).
    DEF 14A
  8. Pay
    Inovio Pharmaceuticals CEO pay fell 31% to $2.4M. The stock fell 67% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 7, 2026FY2025
Annual report10-KMar 12, 2026FY2025
Proxy statementDEF 14AApr 7, 2025FY2024
Annual report10-KMar 18, 2025FY2024
Proxy statementDEF 14AApr 11, 2024FY2023
Annual report10-KMar 6, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data